Tucidinostat
- Generic Name
- Tucidinostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H19FN4O2
- CAS Number
- 1616493-44-7
- Unique Ingredient Identifier
- 87CIC980Y0
- Indication
Investigated for use/treatment in cancer/tumors (unspecified).
- Associated Conditions
- -
- Associated Therapies
- -
Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- Chipscreen Biosciences, Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT03974243
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT03853044
- Locations
- 🇨🇳
Ruijin hospital, Shanghai, Shanghai, China
A Clinical Trial of the Low Dose Chidamide in the Management of Refractory ITP
- First Posted Date
- 2019-02-12
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Shandong University
- Target Recruit Count
- 30
- Registration Number
- NCT03838354
- Locations
- 🇨🇳
Qilu hospital, Shandong University, Jinan, Shandong, China
Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL
- First Posted Date
- 2019-01-29
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Huiqiang Huang
- Target Recruit Count
- 40
- Registration Number
- NCT03820596
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China
🇨🇳Department of hematology department, Nanfang hospital, Guangzhou, Guangdong, China
🇨🇳Guangdong General Hospital; Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Maintenance Treatment of Chidamide in Stage IV or Relapsed/Refractory Extranodal NK/T-cell Lymphoma
- Conditions
- First Posted Date
- 2018-08-15
- Last Posted Date
- 2018-08-15
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 32
- Registration Number
- NCT03630731
- Locations
- 🇨🇳
Cancer Hospital and Institute, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, Beijing, China
Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2022-01-03
- Target Recruit Count
- 69
- Registration Number
- NCT03629873
- Locations
- 🇨🇳
Hematological Department, People's Hospital of Jiangsu Province, Nanjing, Jiangsu, China
Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients
- Conditions
- Interventions
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- Peking University
- Target Recruit Count
- 114
- Registration Number
- NCT03617432
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2018-08-02
- Lead Sponsor
- Peking University
- Target Recruit Count
- 43
- Registration Number
- NCT03611231
- Locations
- 🇨🇳
Beijing, Beijing, Beijing, China
Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- Peng Liu
- Target Recruit Count
- 25
- Registration Number
- NCT03605056
- Locations
- 🇨🇳
180 Fenglin Road, Shanghai, Shanghai, China
Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 30
- Registration Number
- NCT03602131
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.